Since the introduction of sorafenib in 2007(1),a tyrosine kinase inhibitor(TKI),there have been notable advancements in systemic therapy for advanced-stage hepatocellular carcinoma(HCC).Although the European Associati...Since the introduction of sorafenib in 2007(1),a tyrosine kinase inhibitor(TKI),there have been notable advancements in systemic therapy for advanced-stage hepatocellular carcinoma(HCC).Although the European Association for the Study of the Liver(EASL)Clinical Practice Guidelines regarding the management of HCC was published in 2018(2),recent progress,including the advent of several immune checkpoint inhibitors(ICIs),necessitated the revision of this guideline.Therefore,the EASL published a position paper to address the additional improvements on systemic therapy for HCC(3).Here,we aimed to summarize this position paper and comment on some updated points.展开更多
文摘Since the introduction of sorafenib in 2007(1),a tyrosine kinase inhibitor(TKI),there have been notable advancements in systemic therapy for advanced-stage hepatocellular carcinoma(HCC).Although the European Association for the Study of the Liver(EASL)Clinical Practice Guidelines regarding the management of HCC was published in 2018(2),recent progress,including the advent of several immune checkpoint inhibitors(ICIs),necessitated the revision of this guideline.Therefore,the EASL published a position paper to address the additional improvements on systemic therapy for HCC(3).Here,we aimed to summarize this position paper and comment on some updated points.
